1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy. Diabetes 2019, 68 DOI: 10.2337/db19-1249-p.Peer-Reviewed Original ResearchGlucose lowering therapiesOptimal therapeutic regimensGlucose lowering medicationsDiabetes quality indicatorsNational InstituteMedicare Advantage enrolleesPatient-centered approachHigh-complexity patientsPerson/yearComorbidity burdenHospitalization visitsTreatment burdenHypoglycemia riskKidney diseaseTherapeutic regimensNational cohortNumber/typeClinical complexityPatientsMedicaid ServicesOptumLabsDiabetesTherapyVisitsAmerican Association1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1607-p.Peer-Reviewed Original ResearchType 1 diabetesClinical complexityRace/ethnicityMale sexYounger ageAsian race/ethnicityHispanic race/ethnicityGlucose-lowering medicationsPoor glycemic controlLong-term complicationsHigh clinical complexityNational InstituteMedicare Advantage enrolleesAdministrative claims datasetEndocrine managementPatient comorbiditiesGlycemic controlTreatment regimenStudy cohortKidney diseasePotential overtreatmentDiabetesFM managementOvertreatmentU.S. adults